Alligator – which has developing mitazalimab on its own after losing Johnson & Johnson as a partner for the drug a few years ...

Faced with a cash crunch, Alligator Biosciences has said it plans to shed up to 70% of its workforce and focus all its ...

Venture capital group Abingworth is reportedly trying to raise up to $1.5 billion in investment funding to support biopharma ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached statistical ...

The world has woken up to a new era, with Donald Trump elected as US president – a huge victory for a political outsider and the 'silent majority' who felt sidelined by the status quo.

Generic drugmaker Accord Healthcare has announced a £50 million ($65 million) investment in the UK that will include the construction of a new medicines manufacturing facility. The new plant ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn ...

In our patients focus month, we speak with Graeme Duncan of Healthcare at Home Ltd on the benefits that home healthcare can bring to patients. Home healthcare is the fastest growing sector in the ...

Assessing the value of new medical interventions and ensuring the appropriate care pathways are in place has become ever more critical as tightening healthcare budgets are combined with aging ...

The UK is squandering the vast resource of NHS patient data because too many obstacles are being placed in front of researchers trying to tap into it – holding back medical advances. That is the ...

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a treatment for relapsed and refractory multiple myeloma (RRMM). The drugmaker ...

AstraZeneca plans to invest a whopping $3.5 billion to expand its R&D and manufacturing operations in the US by 2026, as part of a drive to raise its revenues to $80 billion by the end of the decade.